Galderma said Monday that Harrison will lead the U.S. and Canada teams. He joined Galderma U.S. in 2014 as the vice president and GM of the company’s Self-Medication Business Unit, which includes its flagship brand Cetaphil. Before coming to Galderma, he held numerous vice president positions at Novartis.
Under his leadership at Galderma, the Self-Medication Business Unit has grown significantly and launched several new over-the-counter brands, including Benzac Acne Solutions, a full line of acne treatment products; Excipial Skin Solutions, a therapeutic skin care line for challenged skin; Qilib Hair Regrowth + Revitalization System, with lines for men and women; and Cetaphil Men and Cetaphil Baby lines.
“Galderma is experiencing a tremendous amount of growth following the launch of eight new products across all three business units in the U.S. over the past 18 months,” stated Stuart Raetzman, chief executive officer of Galderma Pharma S.A. “Miles has the vision and experience to lead our organization at this exciting time of rapid and sustainable growth.”
Galderma noted that its North America affiliate has recently aligned its structure to the company’s global strategy, reorganizing into three business units to accommodate new product launches and acquisitions: the Self-Medication Business Unit, Prescription Business Unit, and Aesthetic and Corrective Business Unit.
The Prescription Business Unit includes the Epiduo Gel and Epiduo Forte Gel acne treatments plus prescription medications for rosacea, such as Soolantra Cream and Oracea Capsules, among others. The Aesthetic and Corrective Business Unit has a broad portfolio of products, including Restylane Silk, Restylane Lyft, Dysport and Sculptra Aesthetic.
To support that growth, last fall Galderma announced the addition of a 100,000-square-foot, $22 million research, development and training building to its current 170,000-square-foot headquarters. The company said the expansion stands to add as many as 350 employees to the current 300 in Fort Worth.
“I am honored to take this leadership position at a time when Galderma is experiencing such fantastic growth and transformation,” Harrison commented. “I am proud to be part of a company consistently trusted by doctors and patients that is truly changing people’s lives with its solutions for skin health. We are committed to meeting the dermatological needs of people throughout their lives, and we will continue to deliver innovative medical solutions to health care professionals, patients and consumers.”